Silver prices experienced a dramatic and historic sell-off on Friday, tumbling over 30% as a surging U.S. dollar and political uncertainty rattled markets. Analysts caution the downturn may not be over, with one prominent forewarning of a potential slide to $68 an ounce.
The medical device developer Beta Bionics has received a warning letter from the U.S. Food and Drug Administration, a regulatory action stemming from a facility inspection last summer. The company maintains the letter will not disrupt its operations, manufacturing, or the planned launch of its new insulin patch pump.
While many AI stocks soared in 2025, Salesforce shares faced significant headwinds. Despite a challenging year, the cloud software giant's robust fundamentals and reasonable valuation suggest it may be poised for a recovery.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
A discounted cash flow valuation of GrainCorp Limited suggests its current share price may not fully reflect its future cash generation potential, indicating a possible opportunity for investors.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
CNBC's Jim Cramer offered a measured take on data security firm Rubrik (NYSE:RBRK), suggesting investors wait for market volatility to settle before considering a position, while highlighting the crowded nature of the sector.
CNBC's Jim Cramer highlights a dramatic turnaround for Meta Platforms, arguing its heavy investment in artificial intelligence is fundamentally reshaping the company's trajectory and market perception.
The rapid adoption of algorithmic decision-making in UK banks has created a critical lag in oversight and accountability structures, leaving institutions exposed to risks that traditional governance models are ill-equipped to manage.
The Federal Reserve left interest rates unchanged, signaling confidence in a solid economy while inflation remains above target. The decision sets up a continued clash with a President demanding deeper cuts.
Dropbox shares have faced significant pressure over the past year, declining roughly 20% and raising questions about its long-term growth trajectory. As the stock trades below key fair value estimates, investors are divided on whether this represents a buying opportunity or reflects deeper challenges in the competitive cloud storage market.
Despite a significant weekly drop in market valuation, G Mining Ventures' substantial institutional ownership and strong yearly returns suggest major investors are focused on the long game, even as recent volatility raises questions.
Amid a volatile market backdrop, several ASX-listed companies, including gold miner Capricorn Metals, are flagged as potentially trading significantly below their intrinsic value, presenting opportunities for discerning investors.
The release of over three million documents by the U.S. Department of Justice has unveiled extensive communications between Jeffrey Epstein and a global network of powerful figures, raising fresh questions about influence, access, and accountability.
The Justice Department faces questions over its release of Epstein investigation records, which included a photograph of Donald Trump with his face obscured. The disclosure, part of a three-million-page document dump, has reignited scrutiny over political sensitivities and transparency in the high-profile case.
The surge in popularity of weight-loss drugs like Ozempic and Wegovy is sending shockwaves far beyond the pharmacy, fundamentally altering consumer spending, challenging major corporations, and forcing a broad economic recalibration.
Capital Management Corp's significant stake increase in investment bank Moelis & Company is being viewed by market observers as a strategic wager on a potential rebound in mergers and acquisitions activity.
As the TSX rides a wave of positive earnings momentum, adventurous investors are turning their gaze to the penny stock arena. We analyze three micro-cap companies—Automotive Finco, Aurora Spine, and Wilton Resources—that are generating buzz, weighing their potential against significant financial risks.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
